HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Inhibikase Therapeutics (NASDAQ:IKT) and maintains a $5 price target.
June 22, 2023 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Inhibikase Therapeutics (NASDAQ:IKT) and maintains a $5 price target.
The reiterated Buy rating and maintained $5 price target by HC Wainwright & Co. analyst Edward White indicates a positive outlook for Inhibikase Therapeutics. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100